EUVIMEDEUVIMED entdecken
Crossref

Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

Milena Izmirlieva

Value in Health · 2026

DOI: 10.1016/j.jval.2025.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Milena Izmirlieva. Beteiligte Einrichtung: London School of Economics and Political Science (LSE), London, England, UK; GlobalData Plc, London, England, UK. Electronic address: milena.izmirlie…. Hauptthemen laut MEDLINE: Drug Costs, Costs and Cost Analysis, Commerce, Drug Industry. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To assess whether applying official International Reference Pricing (IRP) rules allows accurate prediction of pharmaceutical launch prices in Austria, Bulgaria, Croatia, The Netherlands, and North Macedonia. METHODS: Official pre-2019-reform IRP regulations were examined, with 1 Dutch rule further clarified via primary research. IRP rules were applied precisely to calculate the maximum price under IRP for all new chemical/molecular entities presentations first priced in each country in 2018 and customarily subject to IRP, using POLI pricing and reimbursement data for the referrer and the reference countries. Maximum allowed launch prices under IRP were calculated by using prices available for referencing 1 month before launch, the regulation-specified exchange rate and the definition of what constitutes an acceptable product for referencing. If an identical pack size/formulation was not available or multiple suitable products for referencing existed, the appropriate conversion rules were applied as stated in the IRP regulations. The actual first price was compared with the price calculated under IRP for each new chemical or molecular entity presentation, with several scenarios run to explain discrepancies. RESULTS: The mean absolute percentage error (MAPE) between the actual first price and the forecasted/IRP-based price across the sample was lowest for Bulgaria (3.04%), followed by The Netherlands (4.53%), Austria (4.91%), Croatia (9.63%), and North Macedonia (22.09%). North Macedonia's high MAPE is because the country allows prices to exceed the IRP-based price by up to 20%. MAPE < 10% indicates outstanding model performance. CONCLUSIONS: Precise IRP rules application can accurately predict launch prices in countries where IRP is binding and is the main price-setting method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CostsCosts and Cost AnalysisCommerceDrug IndustryHumansEuropeForecastingPharmaceutical Preparations

Stichwörter der Autor:innen

IRPcost-effectivenessdrug pricingexternal reference pricinginternational reference pricinglaunch price forecasting

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • London School of Economics and Political Science (LSE), London, England, UK; GlobalData Plc, London, England, UK. Electronic address: milena.izmirlieva@globaldata.com.

Zitieren

APA

Izmirlieva, M. (2026). Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries. Value in Health. https://doi.org/10.1016/j.jval.2025.08.003

Vancouver

Izmirlieva M. Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries. Value in Health. 2026. doi:10.1016/j.jval.2025.08.003

BibTeX
@article{Izmirlieva2026,
  author = {Izmirlieva, Milena},
  title = {Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries},
  journal = {Value in Health},
  year = {2026},
  doi = {10.1016/j.jval.2025.08.003}
}
Kostenlos starten →